MX2009012600A - Farmaceutico que contiene el agonista ppar alfa. - Google Patents

Farmaceutico que contiene el agonista ppar alfa.

Info

Publication number
MX2009012600A
MX2009012600A MX2009012600A MX2009012600A MX2009012600A MX 2009012600 A MX2009012600 A MX 2009012600A MX 2009012600 A MX2009012600 A MX 2009012600A MX 2009012600 A MX2009012600 A MX 2009012600A MX 2009012600 A MX2009012600 A MX 2009012600A
Authority
MX
Mexico
Prior art keywords
epithelial cells
meibomian gland
isopropyl
agent
pparî
Prior art date
Application number
MX2009012600A
Other languages
English (en)
Inventor
Yoshikuni Nakamura
Ikuko Hanano
Inouejun
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Publication of MX2009012600A publication Critical patent/MX2009012600A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Se pretende proveer un agente para la promoción del crecimiento de las células epiteliales de la glándula meibomiana y células epiteliales de la córnea, y un agente terapéutico para enfermedades de los ojos tales como la disfunción de la glándula meibomiana y ojos secos. Una preparación que contiene un ingrediente activo, [3-[2-[4-(4isopropil-2-(4-triflluorometil)feni l-5-tiazolil]etil]-5-metil-l,2-bencisoxazol-5-il]oxi-acetato, [4-[3-[2-(4-trifluorometil)fenil-4-isopropil-5-tiazolil]propionil ]2-metilfenoxi]acetato o [4-[3-[2-(2-hidroxi-4-clorofenil)-5-isopr opil-4-oxazolill]propionil]-2-metilfenoxi]acetato o una de sus sales farmacológicamente aceptables se utiliza como el agente para promover el crecimiento de las células epiteliales de la glándula meibomiana o células epiteliales de la córnea y el agente terapéutico para enfermedades de los ojos tal como disfunción de la glándula meibomiana y ojos secos.
MX2009012600A 2007-05-21 2008-05-20 Farmaceutico que contiene el agonista ppar alfa. MX2009012600A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007134183 2007-05-21
PCT/JP2008/059236 WO2008143254A1 (ja) 2007-05-21 2008-05-20 ＰＰＡＲδアゴニスト含有医薬

Publications (1)

Publication Number Publication Date
MX2009012600A true MX2009012600A (es) 2010-03-15

Family

ID=40031950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012600A MX2009012600A (es) 2007-05-21 2008-05-20 Farmaceutico que contiene el agonista ppar alfa.

Country Status (14)

Country Link
US (2) US8802705B2 (es)
EP (1) EP2151438B1 (es)
JP (1) JP5247686B2 (es)
KR (1) KR101508020B1 (es)
CN (1) CN101801941B (es)
BR (1) BRPI0811612A2 (es)
CA (1) CA2687957C (es)
DK (1) DK2151438T3 (es)
ES (1) ES2393424T3 (es)
MX (1) MX2009012600A (es)
PL (1) PL2151438T3 (es)
PT (1) PT2151438E (es)
RU (1) RU2449789C2 (es)
WO (1) WO2008143254A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
WO2008027069A1 (en) 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
EP2952189B1 (en) * 2013-01-31 2019-09-18 Senju Pharmaceutical Co., Ltd. Clear aqueous solution
CA2899292A1 (en) * 2013-01-31 2014-08-07 Senju Pharmaceutical Co., Ltd. Stable aqueous solution
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
EP3744391B1 (en) 2013-04-30 2023-03-01 Alcon Inc. Systems for the treatment of eye conditions
JPWO2016199871A1 (ja) * 2015-06-09 2018-03-29 千寿製薬株式会社 神経麻痺性角膜症の治療薬
JPWO2017195875A1 (ja) * 2016-05-12 2019-03-22 日本ケミファ株式会社 創傷治療剤
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
CN110229886A (zh) * 2019-07-05 2019-09-13 杭州笙源生物科技有限公司 一种PPARγ用于诊断肝衰竭的新用途及试剂盒及试剂盒用于诊断肝衰竭的应用
CN112569179B (zh) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 一种可注射水凝胶体系及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5688765A (en) 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
JP4171529B2 (ja) 1995-06-26 2008-10-22 大正製薬株式会社 点眼剤の充填容器
DE69726182T2 (de) 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
JP2001039976A (ja) 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
TWI284533B (en) 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
WO2002013812A1 (en) * 2000-08-17 2002-02-21 Pershadsingh Harrihar A Methods for treating inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2002069994A2 (en) 2001-03-07 2002-09-12 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
AU2002303156A1 (en) * 2001-03-23 2002-10-08 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
ATE526319T1 (de) 2001-08-10 2011-10-15 Nippon Chemiphar Co Aktivator für den peroxisome proliferator- responsiven rezeptor delta
IL161351A0 (en) * 2001-10-12 2004-09-27 Nippon Chemiphar Co ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR delta
AU2003248070A1 (en) 2002-07-16 2004-02-02 Hanshin Yoki Co., Ltd. Chemical container and method of manufacturing the container
JP2004175749A (ja) * 2002-11-28 2004-06-24 Senju Pharmaceut Co Ltd ドライアイおよびドライアイを伴う疾病の治療剤
JP2005008570A (ja) 2003-06-19 2005-01-13 Santen Pharmaceut Co Ltd 角膜疾患治療剤
ES2357801T3 (es) * 2003-10-24 2011-04-29 Santen Pharmaceutical Co., Ltd. Agente terapéutico para trastorno queratoconjuntival.
JP2006176499A (ja) * 2004-11-25 2006-07-06 Nippon Seibutsu Seizai:Kk 眼疾患治療剤
US20070027184A1 (en) * 2005-07-29 2007-02-01 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
CN101336113B (zh) * 2005-11-28 2015-07-29 千寿制药株式会社 包括ppar激动剂的药物

Also Published As

Publication number Publication date
EP2151438B1 (en) 2012-10-31
RU2009147260A (ru) 2011-06-27
EP2151438A4 (en) 2010-09-08
KR20100037038A (ko) 2010-04-08
PL2151438T3 (pl) 2013-03-29
BRPI0811612A2 (pt) 2014-11-11
JP5247686B2 (ja) 2013-07-24
US8802705B2 (en) 2014-08-12
CA2687957A1 (en) 2008-11-27
RU2449789C2 (ru) 2012-05-10
CN101801941A (zh) 2010-08-11
PT2151438E (pt) 2012-11-15
US20120270910A2 (en) 2012-10-25
WO2008143254A1 (ja) 2008-11-27
US20100190833A1 (en) 2010-07-29
KR101508020B1 (ko) 2015-04-06
JPWO2008143254A1 (ja) 2010-08-12
ES2393424T3 (es) 2012-12-21
CN101801941B (zh) 2012-12-12
CA2687957C (en) 2014-11-25
US9463185B2 (en) 2016-10-11
EP2151438A1 (en) 2010-02-10
US20140343109A1 (en) 2014-11-20
DK2151438T3 (da) 2012-11-26

Similar Documents

Publication Publication Date Title
MX2009012600A (es) Farmaceutico que contiene el agonista ppar alfa.
ES2660571T3 (es) Inhibidores de la proteína tirosina fosfatasa humana y su uso farmacéutico
RU2492167C2 (ru) Производные аминотриазола в качестве агонистов alх
PE20060315A1 (es) Compuestos de tiazol como moduladores de ppar
NZ724602A (en) Ror-gamma modulators and uses thereof
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
RU2017139870A (ru) Новые агонисты npr-b
NO20090834L (no) Anvendelse av azabicykloheksanderivater
TW201808289A (zh) 含阿托平之水性組成物
JP2011516477A5 (es)
WO2010143074A3 (en) Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
RU2017121370A (ru) Противогрибковые агенты
HK1138277A1 (en) Prophylactic and/or therapeutic agent for hyperlipemia
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
EP2170857A4 (en) 3 ', 4', 5-TRIMETHOXYFLAVONE DERIVATIVES AS THE SLEEP SECRETION STIMULATING AGENT, CORRESPONDING METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
EP4003952A1 (en) Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
BR0203517A (pt) Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa
MX2023001001A (es) Agonista del ppar-delta cristalino.
CN103702995A (zh) 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
CN102711758A (zh) 用于治疗眼睛的疾病和病症的基于5-(1h-吡唑-5-基)噻唑的化合物
BRPI0906248B8 (pt) composto, composição farmacêutica para inibir a formação de microtúbulos e método para preparar um composto
CL2007002020A1 (es) Sal xinafoato del etil ester de la 1-[[5-(1(s)-aminoetil)-2-[8-metoxi-2-(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-4(r)-[(ciclopropil-carbonil)amino]-l-prolina; polimorfo cristalino; proceso de preparacion; composicion farmaceutica; y uso para
HRP20140348T1 (hr) Novi sekundarni derivati 8-hidroksikinolin-7-karboksamida
NO20080826L (no) 3-(2-(dimetylamino)metyl(cykloheks-1-yl))fenolmaleat og dets krystallinske former

Legal Events

Date Code Title Description
FG Grant or registration